Fulcrum Therapeutics, Inc. (FULC) has a good chance at potentially staging a comeback with its other pipeline drug pociredir, which is being developed in a phase 1b study for the treatment of patients ...
CAMBRIDGE, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (FULC) ® (Fulcrum) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results